Stemmatters and Gelmetix sign agreement

Stemmatters, a Portuguese regenerative medicine company, has established a partnership with the British company of therapeutic biomaterials Gelmetix. This partnership aims to develop an innovative minimally invasive medical device for the treatment of acute cartilage lesions, based on a new hydrogel designed and developed by Stemmatters. Through this partnership, companies will collaborate and leverage joint resources and skills for the pre-clinical development of the medical device prior to clinical studies in man and subsequent market approval.

“As a company seeking to address the growing burden of cartilage lesions and provide better treatment options to patients, Stemmatters team is very enthusiastic and committed to collaborate with Gelmetix in bringing this product closer to clinical reality.” said Rui Sousa, chairman and CEO of Stemmatters.

Click here to check the full press release at Stemmatters’ website.